FSH levels were lower in postmenopausal women with MetS than in women without MetS and were more closely related to MetS than to SHBG.[34] The authors also suggested that the FSH level reflects the probability of MetS similar to or better than other biomarkers such as CRP, adiponectin, and leptin.[11] In a population-based study, Wang et al found a negative association between FSH and the 10-year risk of atherosclerotic cardiovascular disease (ASCVD) in postmenopausal women in China. The gene discussed is BRD2; the disease is metabolic syndrome.